nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—ADRA1B—polycystic ovary syndrome	0.42	0.598	CbGaD
Risperidone—ADRA1A—polycystic ovary syndrome	0.283	0.402	CbGaD
Risperidone—Function kidney decreased—Metformin—polycystic ovary syndrome	0.00495	0.0749	CcSEcCtD
Risperidone—Tonsillitis—Metformin—polycystic ovary syndrome	0.00428	0.0647	CcSEcCtD
Risperidone—Dapiprazole—ADRA1D—polycystic ovary syndrome	0.00318	0.322	CrCbGaD
Risperidone—Dapiprazole—ADRA1B—polycystic ovary syndrome	0.00271	0.275	CrCbGaD
Risperidone—Sinus congestion—Metformin—polycystic ovary syndrome	0.00217	0.0328	CcSEcCtD
Risperidone—Hypothermia—Metformin—polycystic ovary syndrome	0.00193	0.0292	CcSEcCtD
Risperidone—Body temperature decreased—Metformin—polycystic ovary syndrome	0.00193	0.0292	CcSEcCtD
Risperidone—Dapiprazole—ADRA1A—polycystic ovary syndrome	0.00183	0.185	CrCbGaD
Risperidone—Toothache—Metformin—polycystic ovary syndrome	0.00178	0.0269	CcSEcCtD
Risperidone—Upset stomach—Metformin—polycystic ovary syndrome	0.00165	0.0249	CcSEcCtD
Risperidone—HTR2A—urine—polycystic ovary syndrome	0.00155	0.0382	CbGeAlD
Risperidone—CYP3A4—urine—polycystic ovary syndrome	0.00143	0.0353	CbGeAlD
Risperidone—CYP2D6—urine—polycystic ovary syndrome	0.00141	0.0348	CbGeAlD
Risperidone—Fungal infection—Metformin—polycystic ovary syndrome	0.0014	0.0212	CcSEcCtD
Risperidone—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00134	0.0202	CcSEcCtD
Risperidone—Rigors—Metformin—polycystic ovary syndrome	0.00133	0.02	CcSEcCtD
Risperidone—H1F0—embryo—polycystic ovary syndrome	0.0013	0.0321	CbGeAlD
Risperidone—Blood disorder—Metformin—polycystic ovary syndrome	0.0013	0.0196	CcSEcCtD
Risperidone—Chest discomfort—Metformin—polycystic ovary syndrome	0.00122	0.0185	CcSEcCtD
Risperidone—H1F0—adrenal cortex—polycystic ovary syndrome	0.00106	0.0263	CbGeAlD
Risperidone—Paliperidone—ADRA1B—polycystic ovary syndrome	0.001	0.102	CrCbGaD
Risperidone—H1F0—endometrium—polycystic ovary syndrome	0.000951	0.0235	CbGeAlD
Risperidone—Ear pain—Metformin—polycystic ovary syndrome	0.00092	0.0139	CcSEcCtD
Risperidone—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000899	0.0222	CbGeAlD
Risperidone—H1F0—uterus—polycystic ovary syndrome	0.000876	0.0216	CbGeAlD
Risperidone—Nasal congestion—Metformin—polycystic ovary syndrome	0.000862	0.013	CcSEcCtD
Risperidone—H1F0—pituitary gland—polycystic ovary syndrome	0.00086	0.0212	CbGeAlD
Risperidone—H1F0—adipose tissue—polycystic ovary syndrome	0.000857	0.0211	CbGeAlD
Risperidone—Renal impairment—Metformin—polycystic ovary syndrome	0.000825	0.0125	CcSEcCtD
Risperidone—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.000805	0.0122	CcSEcCtD
Risperidone—Lethargy—Metformin—polycystic ovary syndrome	0.000801	0.0121	CcSEcCtD
Risperidone—Pain in extremity—Metformin—polycystic ovary syndrome	0.000785	0.0119	CcSEcCtD
Risperidone—Migraine—Metformin—polycystic ovary syndrome	0.000773	0.0117	CcSEcCtD
Risperidone—H1F0—adrenal gland—polycystic ovary syndrome	0.000769	0.019	CbGeAlD
Risperidone—HTR2B—adrenal cortex—polycystic ovary syndrome	0.000767	0.0189	CbGeAlD
Risperidone—Dehydration—Metformin—polycystic ovary syndrome	0.00073	0.011	CcSEcCtD
Risperidone—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000717	0.0108	CcSEcCtD
Risperidone—H1F0—female gonad—polycystic ovary syndrome	0.000717	0.0177	CbGeAlD
Risperidone—H1F0—vagina—polycystic ovary syndrome	0.000712	0.0176	CbGeAlD
Risperidone—Breast disorder—Metformin—polycystic ovary syndrome	0.00071	0.0107	CcSEcCtD
Risperidone—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000702	0.0106	CcSEcCtD
Risperidone—HTR2B—endometrium—polycystic ovary syndrome	0.000685	0.0169	CbGeAlD
Risperidone—Abdominal distension—Metformin—polycystic ovary syndrome	0.000683	0.0103	CcSEcCtD
Risperidone—Influenza—Metformin—polycystic ovary syndrome	0.000679	0.0103	CcSEcCtD
Risperidone—Paliperidone—ADRA1A—polycystic ovary syndrome	0.000676	0.0685	CrCbGaD
Risperidone—H1F0—endocrine gland—polycystic ovary syndrome	0.000667	0.0164	CbGeAlD
Risperidone—Pancreatitis—Metformin—polycystic ovary syndrome	0.000665	0.0101	CcSEcCtD
Risperidone—Sweating increased—Metformin—polycystic ovary syndrome	0.000661	0.00999	CcSEcCtD
Risperidone—Angina pectoris—Metformin—polycystic ovary syndrome	0.000661	0.00999	CcSEcCtD
Risperidone—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000651	0.00983	CcSEcCtD
Risperidone—Neutropenia—Metformin—polycystic ovary syndrome	0.000635	0.00959	CcSEcCtD
Risperidone—HTR2B—uterus—polycystic ovary syndrome	0.000631	0.0156	CbGeAlD
Risperidone—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000631	0.00953	CcSEcCtD
Risperidone—HTR2B—adipose tissue—polycystic ovary syndrome	0.000617	0.0152	CbGeAlD
Risperidone—Drowsiness—Metformin—polycystic ovary syndrome	0.000605	0.00914	CcSEcCtD
Risperidone—Infestation—Metformin—polycystic ovary syndrome	0.000605	0.00914	CcSEcCtD
Risperidone—Infestation NOS—Metformin—polycystic ovary syndrome	0.000605	0.00914	CcSEcCtD
Risperidone—ADRA2C—adrenal cortex—polycystic ovary syndrome	0.000604	0.0149	CbGeAlD
Risperidone—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000593	0.00896	CcSEcCtD
Risperidone—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000572	0.00865	CcSEcCtD
Risperidone—HTR2B—adrenal gland—polycystic ovary syndrome	0.000554	0.0137	CbGeAlD
Risperidone—Bradycardia—Metformin—polycystic ovary syndrome	0.000553	0.00836	CcSEcCtD
Risperidone—KCNH2—endometrium—polycystic ovary syndrome	0.000547	0.0135	CbGeAlD
Risperidone—Rhinitis—Metformin—polycystic ovary syndrome	0.000545	0.00823	CcSEcCtD
Risperidone—Hepatitis—Metformin—polycystic ovary syndrome	0.000543	0.00821	CcSEcCtD
Risperidone—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000541	0.00817	CcSEcCtD
Risperidone—ADRA2C—endometrium—polycystic ovary syndrome	0.000539	0.0133	CbGeAlD
Risperidone—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000535	0.00808	CcSEcCtD
Risperidone—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000534	0.00806	CcSEcCtD
Risperidone—HTR1B—endocrine gland—polycystic ovary syndrome	0.000533	0.0132	CbGeAlD
Risperidone—HTR2B—vagina—polycystic ovary syndrome	0.000513	0.0127	CbGeAlD
Risperidone—ADRA1A—adipose tissue—polycystic ovary syndrome	0.00051	0.0126	CbGeAlD
Risperidone—Eye disorder—Metformin—polycystic ovary syndrome	0.000508	0.00767	CcSEcCtD
Risperidone—Flushing—Metformin—polycystic ovary syndrome	0.000504	0.00762	CcSEcCtD
Risperidone—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000504	0.00762	CcSEcCtD
Risperidone—KCNH2—uterus—polycystic ovary syndrome	0.000504	0.0124	CbGeAlD
Risperidone—DRD2—pituitary gland—polycystic ovary syndrome	0.000502	0.0124	CbGeAlD
Risperidone—HTR2A—embryo—polycystic ovary syndrome	0.0005	0.0123	CbGeAlD
Risperidone—ADRA2C—uterus—polycystic ovary syndrome	0.000497	0.0123	CbGeAlD
Risperidone—HTR1A—adrenal gland—polycystic ovary syndrome	0.000496	0.0122	CbGeAlD
Risperidone—KCNH2—pituitary gland—polycystic ovary syndrome	0.000495	0.0122	CbGeAlD
Risperidone—Angiopathy—Metformin—polycystic ovary syndrome	0.000493	0.00745	CcSEcCtD
Risperidone—Immune system disorder—Metformin—polycystic ovary syndrome	0.000491	0.00741	CcSEcCtD
Risperidone—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.00049	0.0074	CcSEcCtD
Risperidone—ADRA2C—pituitary gland—polycystic ovary syndrome	0.000488	0.012	CbGeAlD
Risperidone—Chills—Metformin—polycystic ovary syndrome	0.000487	0.00736	CcSEcCtD
Risperidone—ADRA2C—adipose tissue—polycystic ovary syndrome	0.000486	0.012	CbGeAlD
Risperidone—HTR7—adrenal gland—polycystic ovary syndrome	0.000474	0.0117	CbGeAlD
Risperidone—Erythema—Metformin—polycystic ovary syndrome	0.000473	0.00714	CcSEcCtD
Risperidone—Malnutrition—Metformin—polycystic ovary syndrome	0.000473	0.00714	CcSEcCtD
Risperidone—Iloperidone—ADRA1A—polycystic ovary syndrome	0.000473	0.0479	CrCbGaD
Risperidone—Flatulence—Metformin—polycystic ovary syndrome	0.000466	0.00704	CcSEcCtD
Risperidone—Dysgeusia—Metformin—polycystic ovary syndrome	0.000463	0.007	CcSEcCtD
Risperidone—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000457	0.0113	CbGeAlD
Risperidone—Muscle spasms—Metformin—polycystic ovary syndrome	0.000455	0.00687	CcSEcCtD
Risperidone—Vision blurred—Metformin—polycystic ovary syndrome	0.000446	0.00673	CcSEcCtD
Risperidone—Tremor—Metformin—polycystic ovary syndrome	0.000443	0.00669	CcSEcCtD
Risperidone—KCNH2—adrenal gland—polycystic ovary syndrome	0.000442	0.0109	CbGeAlD
Risperidone—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000439	0.00663	CcSEcCtD
Risperidone—HRH1—endometrium—polycystic ovary syndrome	0.000438	0.0108	CbGeAlD
Risperidone—ADRA2C—adrenal gland—polycystic ovary syndrome	0.000436	0.0108	CbGeAlD
Risperidone—HTR1A—endocrine gland—polycystic ovary syndrome	0.00043	0.0106	CbGeAlD
Risperidone—ADRA2A—endometrium—polycystic ovary syndrome	0.00043	0.0106	CbGeAlD
Risperidone—Malaise—Metformin—polycystic ovary syndrome	0.000426	0.00644	CcSEcCtD
Risperidone—Syncope—Metformin—polycystic ovary syndrome	0.000424	0.00641	CcSEcCtD
Risperidone—Palpitations—Metformin—polycystic ovary syndrome	0.000418	0.00631	CcSEcCtD
Risperidone—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000416	0.00628	CcSEcCtD
Risperidone—KCNH2—female gonad—polycystic ovary syndrome	0.000412	0.0102	CbGeAlD
Risperidone—HTR7—endocrine gland—polycystic ovary syndrome	0.000411	0.0101	CbGeAlD
Risperidone—KCNH2—vagina—polycystic ovary syndrome	0.000409	0.0101	CbGeAlD
Risperidone—Hypertension—Metformin—polycystic ovary syndrome	0.000408	0.00617	CcSEcCtD
Risperidone—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000407	0.01	CbGeAlD
Risperidone—ADRA2C—female gonad—polycystic ovary syndrome	0.000406	0.01	CbGeAlD
Risperidone—ADRA2C—vagina—polycystic ovary syndrome	0.000404	0.00997	CbGeAlD
Risperidone—Myalgia—Metformin—polycystic ovary syndrome	0.000403	0.00608	CcSEcCtD
Risperidone—Chest pain—Metformin—polycystic ovary syndrome	0.000403	0.00608	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.0004	0.00604	CcSEcCtD
Risperidone—Discomfort—Metformin—polycystic ovary syndrome	0.000398	0.00601	CcSEcCtD
Risperidone—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000397	0.00979	CbGeAlD
Risperidone—ADRA2A—uterus—polycystic ovary syndrome	0.000397	0.00978	CbGeAlD
Risperidone—HRH1—adipose tissue—polycystic ovary syndrome	0.000395	0.00974	CbGeAlD
Risperidone—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000389	0.00961	CbGeAlD
Risperidone—DRD2—endocrine gland—polycystic ovary syndrome	0.000389	0.00959	CbGeAlD
Risperidone—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000388	0.00957	CbGeAlD
Risperidone—Oedema—Metformin—polycystic ovary syndrome	0.000386	0.00583	CcSEcCtD
Risperidone—Infection—Metformin—polycystic ovary syndrome	0.000383	0.00579	CcSEcCtD
Risperidone—KCNH2—endocrine gland—polycystic ovary syndrome	0.000383	0.00945	CbGeAlD
Risperidone—Shock—Metformin—polycystic ovary syndrome	0.00038	0.00574	CcSEcCtD
Risperidone—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000379	0.00572	CcSEcCtD
Risperidone—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000378	0.00571	CcSEcCtD
Risperidone—Skin disorder—Metformin—polycystic ovary syndrome	0.000375	0.00566	CcSEcCtD
Risperidone—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000373	0.00564	CcSEcCtD
Risperidone—Anorexia—Metformin—polycystic ovary syndrome	0.000368	0.00556	CcSEcCtD
Risperidone—Hypotension—Metformin—polycystic ovary syndrome	0.000361	0.00545	CcSEcCtD
Risperidone—HRH1—adrenal gland—polycystic ovary syndrome	0.000354	0.00874	CbGeAlD
Risperidone—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000352	0.00531	CcSEcCtD
Risperidone—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000348	0.00858	CbGeAlD
Risperidone—Paraesthesia—Metformin—polycystic ovary syndrome	0.000347	0.00524	CcSEcCtD
Risperidone—Dyspnoea—Metformin—polycystic ovary syndrome	0.000344	0.0052	CcSEcCtD
Risperidone—Somnolence—Metformin—polycystic ovary syndrome	0.000343	0.00518	CcSEcCtD
Risperidone—CYP3A5—female gonad—polycystic ovary syndrome	0.00034	0.00839	CbGeAlD
Risperidone—Dyspepsia—Metformin—polycystic ovary syndrome	0.00034	0.00513	CcSEcCtD
Risperidone—CYP3A5—vagina—polycystic ovary syndrome	0.000338	0.00834	CbGeAlD
Risperidone—Decreased appetite—Metformin—polycystic ovary syndrome	0.000336	0.00507	CcSEcCtD
Risperidone—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000333	0.00503	CcSEcCtD
Risperidone—Fatigue—Metformin—polycystic ovary syndrome	0.000333	0.00503	CcSEcCtD
Risperidone—HTR2A—pituitary gland—polycystic ovary syndrome	0.000331	0.00817	CbGeAlD
Risperidone—HRH1—female gonad—polycystic ovary syndrome	0.00033	0.00815	CbGeAlD
Risperidone—Constipation—Metformin—polycystic ovary syndrome	0.00033	0.00499	CcSEcCtD
Risperidone—HRH1—vagina—polycystic ovary syndrome	0.000328	0.0081	CbGeAlD
Risperidone—ABCB1—embryo—polycystic ovary syndrome	0.000328	0.00808	CbGeAlD
Risperidone—ADRA2A—female gonad—polycystic ovary syndrome	0.000324	0.008	CbGeAlD
Risperidone—ADRA2A—vagina—polycystic ovary syndrome	0.000322	0.00795	CbGeAlD
Risperidone—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000318	0.0048	CcSEcCtD
Risperidone—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000316	0.00781	CbGeAlD
Risperidone—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000316	0.00477	CcSEcCtD
Risperidone—HRH1—endocrine gland—polycystic ovary syndrome	0.000307	0.00758	CbGeAlD
Risperidone—Urticaria—Metformin—polycystic ovary syndrome	0.000307	0.00463	CcSEcCtD
Risperidone—Abdominal pain—Metformin—polycystic ovary syndrome	0.000305	0.00461	CcSEcCtD
Risperidone—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000302	0.00744	CbGeAlD
Risperidone—HTR2A—adrenal gland—polycystic ovary syndrome	0.000296	0.0073	CbGeAlD
Risperidone—Asthenia—Metformin—polycystic ovary syndrome	0.000277	0.00418	CcSEcCtD
Risperidone—HTR2A—vagina—polycystic ovary syndrome	0.000274	0.00676	CbGeAlD
Risperidone—Pruritus—Metformin—polycystic ovary syndrome	0.000273	0.00413	CcSEcCtD
Risperidone—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000269	0.00662	CbGeAlD
Risperidone—Diarrhoea—Metformin—polycystic ovary syndrome	0.000264	0.00399	CcSEcCtD
Risperidone—HTR2A—endocrine gland—polycystic ovary syndrome	0.000256	0.00633	CbGeAlD
Risperidone—Dizziness—Metformin—polycystic ovary syndrome	0.000255	0.00386	CcSEcCtD
Risperidone—CYP2D6—female gonad—polycystic ovary syndrome	0.000251	0.0062	CbGeAlD
Risperidone—Vomiting—Metformin—polycystic ovary syndrome	0.000245	0.00371	CcSEcCtD
Risperidone—Rash—Metformin—polycystic ovary syndrome	0.000243	0.00368	CcSEcCtD
Risperidone—Dermatitis—Metformin—polycystic ovary syndrome	0.000243	0.00367	CcSEcCtD
Risperidone—Headache—Metformin—polycystic ovary syndrome	0.000242	0.00365	CcSEcCtD
Risperidone—ABCB1—endometrium—polycystic ovary syndrome	0.00024	0.00592	CbGeAlD
Risperidone—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000237	0.00586	CbGeAlD
Risperidone—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000234	0.00576	CbGeAlD
Risperidone—Nausea—Metformin—polycystic ovary syndrome	0.000229	0.00346	CcSEcCtD
Risperidone—ABCB1—uterus—polycystic ovary syndrome	0.000221	0.00545	CbGeAlD
Risperidone—ABCB1—pituitary gland—polycystic ovary syndrome	0.000217	0.00535	CbGeAlD
Risperidone—ABCB1—adipose tissue—polycystic ovary syndrome	0.000216	0.00533	CbGeAlD
Risperidone—ABCB1—adrenal gland—polycystic ovary syndrome	0.000194	0.00478	CbGeAlD
Risperidone—ABCB1—female gonad—polycystic ovary syndrome	0.000181	0.00446	CbGeAlD
Risperidone—ABCB1—vagina—polycystic ovary syndrome	0.00018	0.00443	CbGeAlD
Risperidone—ABCB1—endocrine gland—polycystic ovary syndrome	0.000168	0.00415	CbGeAlD
Risperidone—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	5.04e-06	2.8e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—LEP—polycystic ovary syndrome	5.03e-06	2.79e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—INS—polycystic ovary syndrome	5.02e-06	2.79e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	5.01e-06	2.78e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	5.01e-06	2.78e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	5e-06	2.77e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	4.98e-06	2.76e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—POMC—polycystic ovary syndrome	4.94e-06	2.74e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	4.93e-06	2.73e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—INS—polycystic ovary syndrome	4.92e-06	2.73e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	4.91e-06	2.72e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IGF1—polycystic ovary syndrome	4.89e-06	2.71e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT2—polycystic ovary syndrome	4.88e-06	2.71e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—POMC—polycystic ovary syndrome	4.86e-06	2.7e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IGF1—polycystic ovary syndrome	4.86e-06	2.69e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT2—polycystic ovary syndrome	4.85e-06	2.69e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	4.85e-06	2.69e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	4.85e-06	2.69e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—INS—polycystic ovary syndrome	4.84e-06	2.68e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.83e-06	2.68e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IRS1—polycystic ovary syndrome	4.82e-06	2.68e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	4.82e-06	2.68e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	4.82e-06	2.67e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	4.82e-06	2.67e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.75e-06	2.64e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.75e-06	2.64e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	4.75e-06	2.63e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.74e-06	2.63e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.73e-06	2.63e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IGF1—polycystic ovary syndrome	4.68e-06	2.6e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.68e-06	2.6e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT2—polycystic ovary syndrome	4.68e-06	2.59e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—POMC—polycystic ovary syndrome	4.64e-06	2.58e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.64e-06	2.58e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	4.64e-06	2.58e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—INS—polycystic ovary syndrome	4.62e-06	2.56e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.61e-06	2.56e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.6e-06	2.55e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.59e-06	2.55e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	4.59e-06	2.55e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	4.59e-06	2.55e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	4.55e-06	2.52e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	4.55e-06	2.52e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	4.54e-06	2.52e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.52e-06	2.51e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.52e-06	2.51e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	4.51e-06	2.5e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.51e-06	2.5e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	4.49e-06	2.49e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IRS1—polycystic ovary syndrome	4.49e-06	2.49e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IRS2—polycystic ovary syndrome	4.48e-06	2.49e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IGF1—polycystic ovary syndrome	4.47e-06	2.48e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT2—polycystic ovary syndrome	4.46e-06	2.48e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—INS—polycystic ovary syndrome	4.46e-06	2.48e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	4.46e-06	2.47e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—TH—polycystic ovary syndrome	4.45e-06	2.47e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.44e-06	2.47e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	4.43e-06	2.46e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.42e-06	2.45e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	4.42e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	4.42e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	4.4e-06	2.44e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—LEP—polycystic ovary syndrome	4.38e-06	2.43e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	4.38e-06	2.43e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	4.36e-06	2.42e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	4.36e-06	2.42e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	4.35e-06	2.42e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	4.35e-06	2.41e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	4.33e-06	2.41e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—INS—polycystic ovary syndrome	4.33e-06	2.4e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	4.33e-06	2.4e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—POMC—polycystic ovary syndrome	4.32e-06	2.4e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	4.32e-06	2.4e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—INS—polycystic ovary syndrome	4.3e-06	2.38e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	4.27e-06	2.37e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	4.24e-06	2.35e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.24e-06	2.35e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	4.21e-06	2.34e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	4.21e-06	2.34e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.2e-06	2.33e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.19e-06	2.32e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.18e-06	2.32e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	4.17e-06	2.32e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IGF1—polycystic ovary syndrome	4.16e-06	2.31e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT2—polycystic ovary syndrome	4.15e-06	2.3e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	4.11e-06	2.28e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.08e-06	2.27e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	4.07e-06	2.26e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	4.06e-06	2.25e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	4.05e-06	2.25e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4e-06	2.22e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.95e-06	2.19e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	3.93e-06	2.18e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.91e-06	2.17e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	3.9e-06	2.16e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.89e-06	2.16e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	3.88e-06	2.15e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.87e-06	2.15e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	3.86e-06	2.14e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	3.85e-06	2.14e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	3.85e-06	2.14e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	3.84e-06	2.13e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.79e-06	2.1e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.79e-06	2.1e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	3.78e-06	2.1e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	3.78e-06	2.1e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—POMC—polycystic ovary syndrome	3.77e-06	2.09e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.75e-06	2.08e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.75e-06	2.08e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	3.75e-06	2.08e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—INS—polycystic ovary syndrome	3.74e-06	2.08e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling by GPCR—IL6—polycystic ovary syndrome	3.74e-06	2.07e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.73e-06	2.07e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	3.73e-06	2.07e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	3.72e-06	2.07e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling by GPCR—IL6—polycystic ovary syndrome	3.71e-06	2.06e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	3.71e-06	2.06e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	3.64e-06	2.02e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.64e-06	2.02e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	3.64e-06	2.02e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	3.62e-06	2.01e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.62e-06	2.01e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.62e-06	2.01e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	3.6e-06	2e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	3.6e-06	2e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.59e-06	1.99e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	3.59e-06	1.99e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	3.59e-06	1.99e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling by GPCR—IL6—polycystic ovary syndrome	3.58e-06	1.99e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	3.57e-06	1.98e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.56e-06	1.98e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	3.54e-06	1.96e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	3.52e-06	1.95e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—INS—polycystic ovary syndrome	3.52e-06	1.95e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	3.5e-06	1.95e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	3.5e-06	1.94e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	3.46e-06	1.92e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.45e-06	1.92e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	3.45e-06	1.91e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	3.45e-06	1.91e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	3.45e-06	1.91e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.44e-06	1.91e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.43e-06	1.91e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.43e-06	1.9e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.42e-06	1.9e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling by GPCR—IL6—polycystic ovary syndrome	3.42e-06	1.9e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.41e-06	1.89e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.38e-06	1.87e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.37e-06	1.87e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.33e-06	1.85e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.31e-06	1.84e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	3.31e-06	1.83e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	3.29e-06	1.83e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	3.29e-06	1.82e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	3.28e-06	1.82e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.28e-06	1.82e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.26e-06	1.81e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	3.25e-06	1.81e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	3.25e-06	1.8e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	3.24e-06	1.8e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	3.24e-06	1.8e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	3.23e-06	1.79e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—INS—polycystic ovary syndrome	3.23e-06	1.79e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	3.22e-06	1.79e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.22e-06	1.79e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.19e-06	1.77e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	3.19e-06	1.77e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.18e-06	1.76e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—IL6—polycystic ovary syndrome	3.18e-06	1.76e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.18e-06	1.76e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.17e-06	1.76e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.17e-06	1.76e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	3.17e-06	1.76e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.13e-06	1.74e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.13e-06	1.74e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	3.12e-06	1.73e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	3.12e-06	1.73e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.11e-06	1.72e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.09e-06	1.72e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	3.07e-06	1.71e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	3.06e-06	1.7e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	3.06e-06	1.7e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.06e-06	1.7e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.06e-06	1.7e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.02e-06	1.68e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.97e-06	1.65e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.97e-06	1.65e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	2.96e-06	1.64e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	2.94e-06	1.63e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.92e-06	1.62e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.91e-06	1.61e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	2.88e-06	1.6e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.87e-06	1.59e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	2.85e-06	1.58e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	2.84e-06	1.58e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.77e-06	1.54e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.76e-06	1.53e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.75e-06	1.53e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.74e-06	1.52e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.71e-06	1.51e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.7e-06	1.5e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	2.68e-06	1.49e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.67e-06	1.48e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	2.64e-06	1.46e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.51e-06	1.39e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.48e-06	1.38e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.45e-06	1.36e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.45e-06	1.36e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.43e-06	1.35e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.43e-06	1.35e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.39e-06	1.33e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	2.39e-06	1.33e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.37e-06	1.31e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.35e-06	1.31e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.34e-06	1.3e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.34e-06	1.3e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.31e-06	1.28e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.29e-06	1.27e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.29e-06	1.27e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.25e-06	1.25e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.24e-06	1.24e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—polycystic ovary syndrome	2.21e-06	1.23e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—polycystic ovary syndrome	2.19e-06	1.22e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	2.18e-06	1.21e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—polycystic ovary syndrome	2.15e-06	1.19e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.13e-06	1.18e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—polycystic ovary syndrome	2.11e-06	1.17e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.08e-06	1.15e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.04e-06	1.13e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.04e-06	1.13e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.02e-06	1.12e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—polycystic ovary syndrome	2.02e-06	1.12e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	2e-06	1.11e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	1.9e-06	1.06e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.89e-06	1.05e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—polycystic ovary syndrome	1.88e-06	1.04e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.86e-06	1.03e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	1.7e-06	9.41e-06	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.64e-06	9.08e-06	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.63e-06	9.03e-06	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	1.58e-06	8.79e-06	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	1.56e-06	8.65e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.53e-06	8.48e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.51e-06	8.37e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.5e-06	8.32e-06	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	1.44e-06	7.97e-06	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.41e-06	7.84e-06	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	1.41e-06	7.83e-06	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	1.38e-06	7.68e-06	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	1.29e-06	7.14e-06	CbGpPWpGaD
